Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy - Wikidata - wikimedia - TriplyDB

Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy

Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy

http://www.wikidata.org/entity/Q34814795

about

The PHACS SMARTT Study: Assessment of the Safety of In Utero Exposure to Antiretroviral Drugs Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP)Nevirapine Concentration in Hair Samples Is a Strong Predictor of Virologic Suppression in a Prospective Cohort of HIV-Infected Patients Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA Trial Lamivudine Concentration in Hair and Prediction of Virologic Failure and Drug Resistance among HIV Patients Receiving Free ART in China Quantifying Isoniazid Levels in Small Hair Samples: A Novel Method for Assessing Adherence during the Treatment of Latent and Active Tuberculosis Hair and plasma data show that lopinavir, ritonavir, and efavirenz all transfer from mother to infant in utero, but only efavirenz transfers via breastfeeding Using the multiphase optimization strategy (MOST) to optimize an HIV care continuum intervention for vulnerable populations: a study protocol.Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202.A cross-sectional study to evaluate second line virological failure and elevated bilirubin as a surrogate for adherence to atazanavir/ritonavir in two urban HIV clinics in Lilongwe, Malawi.HIV-Infected Individuals Who Delay, Decline, or Discontinue Antiretroviral Therapy: Comparing Clinic- and Peer-Recruited Cohorts Antiretroviral concentrations in small hair samples as a feasible marker of adherence in rural Kenya Comparing the novel method of assessing PrEP adherence/exposure using hair samples to other pharmacologic and traditional measures Assessment of HIV antiretroviral therapy adherence by measuring drug concentrations in hair among children in rural Uganda Short communication: Tenofovir diphosphate in dried blood spots as an objective measure of adherence in HIV-infected women.Efficacy and safety of lopinavir/ritonavir versus efavirenz-based antiretroviral therapy in HIV-infected pregnant Ugandan women.Hair concentrations of antiretrovirals predict viral suppression in HIV-infected pregnant and breastfeeding Ugandan women.Using Lopinavir Concentrations in Hair Samples to Assess Treatment Outcomes on Second-Line Regimens Among Asian Children.Implementation and Operational Research: Pulling the Network Together: Quasiexperimental Trial of a Patient-Defined Support Network Intervention for Promoting Engagement in HIV Care and Medication Adherence on Mfangano Island, Kenya Analysis of Antiretrovirals in Single Hair Strands for Evaluation of Drug Adherence with Infrared-Matrix-Assisted Laser Desorption Electrospray Ionization Mass Spectrometry Imaging.Measuring the efficacy of antiretroviral therapy γ-H2AX and other histone post-translational modifications in the clinic.Behavioral intervention improves treatment outcomes among HIV-infected individuals who have delayed, declined, or discontinued antiretroviral therapy: a randomized controlled trial of a novel intervention.Hair Measurements of Cortisol, DHEA, and DHEA to Cortisol Ratio as Biomarkers of Chronic Stress among People Living with HIV in China: Known-Group Validation A single-nucleotide polymorphism in CYP2B6 leads to >3-fold increases in efavirenz concentrations in plasma and hair among HIV-infected women.Microanalysis of the antiretroviral nevirapine in human hair from HIV-infected patients by liquid chromatography-tandem mass spectrometry.Menstrual cycle phase and single tablet antiretroviral medication adherence in women with HIV.Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.Cohort for Tuberculosis Research by the Indo-US Medical Partnership (CTRIUMPH): protocol for a multicentric prospective observational study Emerging antiretroviral drug resistance in sub-Saharan Africa: novel affordable technologies are needed to provide resistance testing for individual and public health benefits.Adherence profiles and therapeutic responses of treatment-naive HIV-infected patients starting boosted atazanavir-based therapy in the ANRS 134-COPHAR 3 trial.Reactions, beliefs and concerns associated with providing hair specimens for medical research among a South African sample: a qualitative approach Isoniazid hair concentrations in children with tuberculosis: a proof of concept study CYP2B6*6 and CYP2B6*18 Predict Long-Term Efavirenz Exposure Measured in Hair Samples in HIV-Positive South African Women Association of self-reported race with AIDS death in continuous HAART users in a cohort of HIV-infected women in the United States Antiretroviral bioanalysis methods of tissues and body biofluids.HIV PrEP Trials: The Road to Success.Short communication: A low-cost method for analyzing nevirapine levels in hair as a marker of adherence in resource-limited settings.Pharmacokinetics of lopinavir/ritonavir and efavirenz in food insecure HIV-infected pregnant and breastfeeding women in Tororo, Uganda.Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202.

P2860

Q26744617-4B4D9D56-8D58-42A0-8BA5-07296E718D86 Q28538457-8A3EC50B-5F59-4181-BF2E-9A528E090B1F Q28548003-1F79D5FE-7612-4AD4-8E64-7AB23B9A537F Q28548288-ADB0CE48-A79F-4D58-919B-F3D750B740C9 Q28551633-9ED6814F-B76B-4098-B027-DDFC48EBE8A8 Q28552186-1941937E-4CED-4C51-8572-FD72526CB1F2 Q30679524-4A09C8A7-F4DE-4133-AB27-06BB214F710F Q33640486-B87D2478-5BF0-4175-BF85-928033366FA3 Q33760652-59999023-6F9A-451D-BFEE-2D9DDA4B5A28 Q33868639-5B472954-22D1-49E3-9B77-3904BF16A321 Q33907350-D83ECC2E-8D16-47A1-9F3F-E47BB000E305 Q34098406-D72DBCC2-3E04-43A1-A3A7-1EE0786DE3FE Q34675000-21500602-BAFD-49A7-875E-16F040750C1E Q35009569-1C30A209-BC32-4772-9110-1AFD65E30333 Q35230243-5B7518CC-5D53-454F-B2C4-3BE190659F1C Q35597592-54C546A6-F4F7-4BA4-ABD9-03587D5046E0 Q35627832-5A62C9F4-90BF-4BC9-A527-3C8562174272 Q35705368-46B9345C-7A5F-4848-9C51-73ECDC229126 Q35797968-C294C311-67FE-4716-AB82-A13C010E7FF5 Q35873971-7CC6B360-7FC6-4613-9B5C-7BDA5729C4F1 Q35983271-BDA2A394-223B-4BD9-BA70-CF7C06654F48 Q36019818-99FE9B45-6401-4E0B-8DAD-A73CA85252FD Q36052895-954AB3EA-F6C5-41C4-91EB-CAE731F12F02 Q36251231-6ED29D4C-EC75-434A-A81E-0810D8F44450 Q36305444-44A25751-D6E3-4345-A0C0-3768EE6AFFA2 Q36336929-2777B5EE-843A-4AC7-BB88-79DA746F4DDC Q36463574-62973286-47FA-4FCE-B403-A9C5EE3E5072 Q36554980-9F2BF600-21FA-4732-BB7C-204044D5FD44 Q36625240-9D53219F-FDA0-41CE-AD7E-34D0E49C12EC Q36669337-0EA72E9B-28C6-4154-A0FB-0396996FA900 Q36785804-E12DA8BC-1F7D-40E9-8EA9-AB3A4BE6B666 Q36808036-888FD459-1C93-4C1F-9618-13B4286059A1 Q36958417-FC5C3204-9DED-4F88-9788-3360BAEB69C8 Q36966640-3DD3D4E9-4231-4D44-8A71-0F7EA22D4FCE Q37272859-19095AE3-27BC-4566-B2BB-AC76E538A22E Q37332868-A4CF0F86-F1EF-47EB-B20B-3BB944806A98 Q37438644-1B3337A9-0B20-4B89-99A2-6B6ABC241C24 Q37460068-2BEC3491-ECAF-42F0-B737-C10CBB55098F Q37600844-1D5E3385-7561-41DA-8556-81F06DD1D6E4 Q37617319-8A4A189F-F810-4AB1-AD65-3A33FA59AD7A

P2860

Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy

http://www.wikidata.org/entity/Q34814795

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Atazanavir concentration in ha ...... omes on antiretroviral therapy

@ast

Atazanavir concentration in ha ...... omes on antiretroviral therapy

@en

Atazanavir concentration in ha ...... omes on antiretroviral therapy

@nl

type

label

Atazanavir concentration in ha ...... omes on antiretroviral therapy

@ast

Atazanavir concentration in ha ...... omes on antiretroviral therapy

@en

Atazanavir concentration in ha ...... omes on antiretroviral therapy

@nl

prefLabel

Atazanavir concentration in ha ...... omes on antiretroviral therapy

@ast

Atazanavir concentration in ha ...... omes on antiretroviral therapy

@en

Atazanavir concentration in ha ...... omes on antiretroviral therapy

@nl

P1433

Q34814795-F4DDAF09-F868-49CD-B7AD-9AC6F616418F

P1476

Q34814795-66444279-52A6-46ED-B4CD-873DCA1EBA04

P2093

Q34814795-02380538-74D5-4B87-A0E7-BCFE0CBC95BF

Q34814795-2E9D3785-6909-40DA-9A03-AB7FC7CEEDD4

Q34814795-31206B0E-C4BF-45A6-A5A6-6DD00555EF25

Q34814795-4A95DEA8-53E8-47CF-8F6A-8E91672CF047

Q34814795-4F371E72-2745-4C9C-9157-2B28FF897CA6

Q34814795-5C110295-B9BD-402E-8B00-D25BD975EF9E

Q34814795-9422161A-007E-44F4-8EB4-BA53F3B0976E

Q34814795-A5837B82-DDF1-4F44-A922-7588935327E6

Q34814795-F517A1A0-987E-4162-BFE7-3D61F7ED168F

Q34814795-F80E2B0A-1D2C-4530-B689-DD7B754FBC78

P2860

Q34814795-028CC972-052E-4708-8DEF-A6D45E6635BF

Q34814795-05ACE3DA-0F3A-4AA7-B1F4-1B62680AB866

Q34814795-0906B237-B5F4-422B-A621-E044151F6EAA

Q34814795-09F2BBBD-3858-4458-818C-100C0EFA7497

Q34814795-0BDCA2EE-2B40-49DC-AF6C-26D60E9712E0

Q34814795-133413E6-7224-4410-AFE3-5CE476C039D1

Q34814795-23AF4DE0-6170-40D0-9B12-03B2CD1E3F5C

Q34814795-2FEBB2DA-6401-4608-8FCA-998B59E9C026

Q34814795-3A89E736-31FF-4022-9065-CA256C93FD78

Q34814795-49F70D6A-5CB0-4AB3-98C2-0FF6E8E7F891

P304

Q34814795-09D98EE3-1782-42D8-A0EE-7385308326D3

P31

Q34814795-73E2C956-F7CB-4449-B8E9-6AA2778CDA60

P356

Q34814795-97BC4A13-0EFE-410D-8528-A4426F71B05C

P407

Q34814795-C7ED64DD-FE1E-47E8-A061-535C75B2E8EA

P433

Q34814795-E4FB05D6-46B5-4C00-B054-65630BA08907

P478

Q34814795-F4894290-AA62-4E7B-87D3-8A58083C6193

P50

Q34814795-B57191BD-2F78-4578-885D-27170A63730F

P577

Q34814795-009EAE81-1BAD-4FEE-80CE-F1A9BAA0AA5D

P5875

Q34814795-8DE788D0-974B-4111-843A-52EAFF192C03

P698

Q34814795-FEC361AE-8BE0-41C2-BBD7-0B2ACAF3F3DB

P921

Q34814795-94F7AF8F-C3DA-45E5-9344-6C2E653E2EBF

P932

Q34814795-943A17B4-46AA-46CD-94DD-38A5322D56D2

P356

P1433

Clinical Infectious Diseases

P1476

Atazanavir concentration in ha ...... omes on antiretroviral therapy

@en

P2093

Gerald B Sharp

http://www.w3.org/2001/XMLSchema#string

Howard Minkoff

http://www.w3.org/2001/XMLSchema#string

Joel Milam

http://www.w3.org/2001/XMLSchema#string

Kathryn Anastos

http://www.w3.org/2001/XMLSchema#string

Mardge H Cohen

http://www.w3.org/2001/XMLSchema#string

Mary Young

http://www.w3.org/2001/XMLSchema#string

Monica Gandhi

http://www.w3.org/2001/XMLSchema#string

Niloufar Ameli

http://www.w3.org/2001/XMLSchema#string

Peter Bacchetti

http://www.w3.org/2001/XMLSchema#string

Ruth M Greenblatt

http://www.w3.org/2001/XMLSchema#string

P2860

Practical and conceptual challenges in measuring antiretroviral adherence.

Hair as a biological specimen for therapeutic drug monitoring.

Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting

Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic

Average adherence to boosted protease inhibitor therapy, rather than the pattern of missed doses, as a predictor of HIV RNA replication.

Protease inhibitor levels in hair strongly predict virologic response to treatment.

Sensitive analysis of anti-HIV drugs, efavirenz, lopinavir and ritonavir, in human hair by liquid chromatography coupled with tandem mass spectrometry

Management of antiretroviral failure and resistance in developing countries.

Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy.

Do we still need a cohort study of women with HIV infection?

P304

1267-1275

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CID/CIR131

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51065405

http://www.w3.org/2001/XMLSchema#string

P698

21507924

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

P932

3079399

http://www.w3.org/2001/XMLSchema#string